Drug Trial Radar · NCT03448978
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Last checked: Nov 20, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
32
Actual
Start
Mar 8, 2018
Primary completion
Apr 19, 2021
Study completion Jun 3, 2021
Sponsor
- Lead sponsor
- Cartesian TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
Descartes-08Biological
autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
FludarabineDrug
intravenous fludarabine
CyclophosphamideDrug
intravenous cyclophosphamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 2 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The Center for Cancer and Blood Disorders
Bethesda, Maryland
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Virgina Cancer Specialists
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.